Prognostic and Clinical Significance of Circulating Cystatin C Levels in Cancer Patients: A Meta-Analysis
6 affiliations
- 1Department of Medical Biochemistry, Faculty of Medicine, Recep Tayyip Erdoğan University, Rize, Türkiye.
- 2Al Mutma’innah Maa O Shishu Hospital, Rajarbag Shareef, Dhaka, Bangladesh.
- 3Department of Biostatistics, Faculty of Medicine, Cukurova University, Adana, Türkiye.
- 4Department of Translational Medicine, Faculty of Medicine, Cukurova University, Adana, Türkiye.
- 5Department of Pulmonary, Faculty of Medicine, Cukurova University, Adana, Türkiye.
- 6Division of Biochemistry, Department of Basic Medical Sciences, Faculty of Medicine, Recep Tayyip Erdoğan University, Rize, Türkiye.
Abstract
Background:: Cystatin C (CysC) exhibits both tumor-promoting and tumor-suppressing effects. Although elevated circulating CysC levels have been reported in multiple cancer types, studies assessing its prognostic value have produced conflicting results. This study aims to resolve these discrepancies and clarify the role of CysC as a prognostic marker.
Methods:: A literature search was conducted in multiple databases. The pooled Hazard Ratio (HR) with a 95% confidence interval (CI) was calculated to assess the prognostic significance of CysC, while the Odds Ratio (OR) with a 95% CI was used to evaluate its clinicopathological associations in various cancers. Sources of heterogeneity were identified by performing subgroup and meta-regression analyses. The study was registered in PROSPERO.
Results:: Twelve studies comprising 7678 patients were included in the analysis. The study found that elevated CysC levels were associated with worse overall survival (OS); pooled HR = 1.60, 95% CI = 1.22–2.10; p = 0.0006, I² = 84%. Subgroup analyses indicated that renal cancer, follow-up time >2.5 years, and study location (China) were linked to worse survival, and all subgroups contributed to significant heterogeneity. Sensitivity analysis confirmed the robustness of the pooled results. Additionally, CysC levels correlated with T stage, N stage, TNM stage, and sex, but not with smoking.
Conclusion:: Elevated CysC is associated with worse overall survival, but significant heterogeneity warrants cautious interpretation.
Related
- Circulating leucine-rich α-2 glycoprotein 1 and its prognostic significance in established heart failure
- Prognostic Significance and Clinical Robustness of the HALP Score in Super-Elderly Patients Undergoing Curative Gastrectomy for Gastric Cancer: A Multicenter Retrospective Cohort Study.
- Prognostic Significance of Serum Sodium in Patients With Acute Pulmonary Embolism
- Evaluating the role of serum cystatin C as a circulating biomarker of diabetic retinopathy from a rural Indian population
- Author’s response to letter of editor for Evaluating the role of serum cystatin C as a circulating biomarker of diabetic retinopathy from a rural Indian population
BibTeX
@article{tory2026prognostic,
title = {{Prognostic and Clinical Significance of Circulating Cystatin C Levels in Cancer Patients: A Meta-Analysis}},
author = {Sehreen Tory and Md. Mojahidur Hasan and Yusuf Kemal Arslan and Yasemin Saygideger and Yusuf Tutar},
journal = {Asian Pacific Journal of Cancer Prevention : APJCP},
year = {2026},
month = jun,
doi = {10.31557/apjcp.2026.27.6.2243},
url = {https://doi.org/10.31557/apjcp.2026.27.6.2243},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Prognostic and Clinical Significance of Circulating Cystatin C Levels in Cancer Patients: A Meta-Analysis
AU - Sehreen Tory
AU - Md. Mojahidur Hasan
AU - Yusuf Kemal Arslan
AU - Yasemin Saygideger
AU - Yusuf Tutar
PY - 2026
DA - 2026/06/21
JO - Asian Pacific Journal of Cancer Prevention : APJCP
DO - 10.31557/apjcp.2026.27.6.2243
UR - https://doi.org/10.31557/apjcp.2026.27.6.2243
AB - Background:: Cystatin C (CysC) exhibits both tumor-promoting and tumor-suppressing effects. Although elevated circulating CysC levels have been reported in multiple cancer types, studies assessing its prognostic value have produced conflicting results. This study aims to resolve these discrepancies and clarify the role of CysC as a prognostic marker. Methods:: A literature search was conducted in multiple databases. The pooled Hazard Ratio (HR) with a 95% confidence interval (CI) was calculated to assess the prognostic significance of CysC, while the Odds Ratio (OR) with a 95% CI was used to evaluate its clinicopathological associations in various cancers. Sources of heterogeneity were identified by performing subgroup and meta-regression analyses. The study was registered in PROSPERO. Results:: Twelve studies comprising 7678 patients were included in the analysis. The study found that elevated CysC levels were associated with worse overall survival (OS); pooled HR = 1.60, 95% CI = 1.22–2.10; p = 0.0006, I² = 84%. Subgroup analyses indicated that renal cancer, follow-up time >2.5 years, and study location (China) were linked to worse survival, and all subgroups contributed to significant heterogeneity. Sensitivity analysis confirmed the robustness of the pooled results. Additionally, CysC levels correlated with T stage, N stage, TNM stage, and sex, but not with smoking. Conclusion:: Elevated CysC is associated with worse overall survival, but significant heterogeneity warrants cautious interpretation.
SN - 1513-7368
SN - 2476-762X
ER -